The Indian IPO market continues to witness significant activity in the SME segment, with Aakaar Medical Technologies emerging as one of the most anticipated offerings in June 2025. This aesthetic medical equipment company has garnered considerable investor attention as it prepares to list on the NSE SME platform with a public offering worth ₹27 crores. The company, which has been operating in the aesthetic medical industry for over two decades, represents an interesting investment opportunity in the rapidly growing healthcare and beauty technology sector.
Aakaar Medical Technologies Limited has established itself as a prominent player in India’s aesthetic medical services industry, dealing with a comprehensive range of products from in-clinic medical devices to home care solutions and advanced aesthetic machines. The company’s decision to go public comes at a time when the aesthetic medical industry is experiencing unprecedented growth, driven by increasing awareness about aesthetic treatments and rising disposable incomes among urban consumers. With a track record spanning more than 24 years and a diverse product portfolio, the company aims to leverage the IPO proceeds to expand its market presence and enhance its technological capabilities.
Table of Contents
Aakaar Medical Technologies IPO: Key Details and Timeline
The Aakaar Medical Technologies IPO opened on June 20, 2025, and will close on June 24, 2025, with the price band set at ₹68 to ₹72 per share. The company has structured the offering as a book build issue worth ₹27 crores under the SME IPO category, making it accessible to retail investors who are increasingly showing interest in small and medium enterprise listings.
The minimum lot size for application is 1,600 shares, requiring a minimum investment of ₹1,15,200 for retail investors. This relatively high minimum investment amount reflects the company’s positioning in the premium segment of the aesthetic medical equipment market. The IPO structure follows the standard allocation pattern with 35% reserved for retail investors, 50% for qualified institutional buyers (QIB), and 15% for non-institutional investors (NII).
The timeline for the IPO process has been carefully planned to ensure smooth execution. Following the closure of the issue on June 24, 2025, the allotment is scheduled for June 25, 2025, with refund initiation on June 26, 2025, and the final listing on NSE SME platform on June 27, 2025. This tight schedule reflects the efficiency of modern IPO processes and the company’s eagerness to commence trading operations.
Company Profile and Business Model Analysis
Aakaar Medical Technologies Limited was established in 2013 and operates as an aesthetic medical company with a wide range of specialized products and devices, boasting over 24 years of expertise in the aesthetic services sector. The company has built a robust business model centered around the distribution and supply of advanced aesthetic medical equipment and related products.
The company operates under the name “Aakaar Medical Technologies Pvt Ltd” (formerly Coherent Medical Systems) and has established itself as one of the prominent distributors and suppliers of skin and hair care treatment products and medical equipment. Their product portfolio includes body sculpting equipment, intense pulse light devices, and various other aesthetic medical technologies that cater to the growing demand for non-invasive cosmetic treatments.
The business model focuses on serving both clinical and home-care segments, providing comprehensive solutions for aesthetic medical practitioners and individual consumers. The company’s product range is described as very diverse and unique, covering everything from in-clinic use products to home care solutions and sophisticated medical machines. This diversification strategy has helped the company maintain steady growth and reduce dependency on any single product category.
The company’s operational footprint spans across India, with a strong distribution network that enables it to serve customers in multiple states. Their business approach combines direct sales with strategic partnerships, allowing them to maintain competitive pricing while ensuring widespread product availability.
Financial Performance and Growth Trajectory
In the financial year 2024-25, Aakaar Medical Technologies reported revenue from operations of ₹61.58 crore, representing a significant increase of 33.5% from ₹46.11 crore in the previous financial year. This impressive growth rate demonstrates the company’s ability to capitalize on the expanding aesthetic medical market and effectively execute its business strategy.
The company’s financial performance has been particularly strong, with revenue increasing by 33% and profit after tax (PAT) rising by an impressive 110% between the financial years ending March 31, 2024, and March 31, 2025. This dramatic improvement in profitability indicates enhanced operational efficiency and better cost management practices.
Current financial metrics show the company has a market capitalization of ₹102 crore, with annual revenue of ₹61.6 crore and profit of ₹6.04 crore. However, investors should note that the company maintains high debtors of 166 days, which could impact cash flow management and requires careful monitoring.
The strong financial performance reflects the company’s successful positioning in the high-growth aesthetic medical equipment market. The significant improvement in profitability margins suggests that the company has been able to optimize its operations while maintaining competitive pricing for its products.
Grey Market Premium and Market Sentiment
The Grey Market Premium (GMP) serves as an important indicator of market sentiment and investor confidence in upcoming IPOs. For Aakaar Medical Technologies, the GMP data provides insights into how the market perceives the company’s valuation and growth prospects. Current available information indicates that the Aakaar Medical IPO GMP is not yet available in the market, which is typical for newly announced IPOs where trading activity is still developing.
The absence of established GMP data suggests that investors are still evaluating the company’s fundamentals and market positioning. This presents both an opportunity and a risk for potential investors, as the lack of grey market activity could indicate either cautious optimism or limited awareness among retail investors.
Market sentiment towards SME IPOs has generally been positive in recent months, with investors showing increased appetite for growth-oriented small and medium enterprises. The aesthetic medical equipment sector, in particular, has attracted significant attention due to its growth potential and the increasing acceptance of cosmetic treatments among Indian consumers.
Investors should monitor the development of GMP activity as the IPO progresses, as this will provide valuable insights into market demand and potential listing performance. The establishment of active grey market trading typically indicates strong investor interest and can serve as a predictor of listing day performance.
Investment Analysis and Risk Assessment
The investment proposition for Aakaar Medical Technologies centers around the company’s established position in the growing aesthetic medical equipment market. With over two decades of industry experience and a diverse product portfolio, the company offers investors exposure to a sector that benefits from favorable demographic trends and increasing consumer spending on aesthetic treatments.
The company’s strong financial performance, particularly the 110% increase in profit after tax, demonstrates management’s ability to scale operations efficiently. The 33% revenue growth indicates healthy demand for the company’s products and successful market penetration strategies. These metrics suggest that the company is well-positioned to benefit from continued market expansion.
However, potential investors should consider several risk factors. The company’s high debtors of 166 days could impact cash flow management and working capital efficiency. This extended collection period may affect the company’s ability to respond quickly to market opportunities or manage unexpected challenges.
The aesthetic medical equipment market is highly competitive, with both domestic and international players vying for market share. The company faces competition from established medical device manufacturers and new entrants attracted by the sector’s growth potential. Additionally, regulatory changes in the healthcare sector could impact product approvals and market access.
The relatively high minimum investment requirement of ₹1,15,200 may limit accessibility for some retail investors, potentially affecting the breadth of market participation. This could impact liquidity in the secondary market following listing.
IPO Details and Investment Information
| Parameter | Details |
|---|---|
| IPO Open Date | June 20, 2025 |
| IPO Close Date | June 24, 2025 |
| Price Band | ₹68 – ₹72 per share |
| Lot Size | 1,600 shares |
| Minimum Investment | ₹1,15,200 |
| Issue Size | ₹27 crores |
| Total Shares Offered | 37,50,400 equity shares |
| Face Value | ₹10 per share |
| Listing Platform | NSE SME |
| Tentative Listing Date | June 27, 2025 |
| Registrar | Bigshare Services Pvt Ltd |
Financial Snapshot
| Metric | FY 2024-25 | FY 2023-24 | Growth |
|---|---|---|---|
| Revenue | ₹61.58 crore | ₹46.11 crore | 33.5% |
| Profit After Tax | ₹6.04 crore | Data not specified | 110% |
| Market Cap | ₹102 crore | – | – |
| Debtors Days | 166 days | – | – |
Conclusion and Investment Recommendation
Aakaar Medical Technologies represents an intriguing investment opportunity in the rapidly expanding aesthetic medical equipment sector. The company’s strong financial performance, with 33% revenue growth and 110% increase in profit after tax, demonstrates its ability to capitalize on favorable market conditions and execute its business strategy effectively.
The aesthetic medical industry’s growth prospects remain robust, driven by increasing consumer awareness, rising disposable incomes, and growing acceptance of cosmetic treatments. Aakaar’s established market presence and diverse product portfolio position it well to benefit from these trends.
However, potential investors should carefully consider the risks, including the company’s extended debtor collection period and the competitive nature of the medical equipment market. The relatively high minimum investment requirement may also limit the investor base and affect post-listing liquidity.
For investors seeking exposure to the healthcare and aesthetic medical equipment sector, Aakaar Medical Technologies IPO offers an opportunity to participate in a company with demonstrated growth and profitability. However, as with all IPO investments, thorough due diligence and consideration of individual risk tolerance are essential before making investment decisions.
Read More: Oswal Pumps Share Price: Stock Lists at 3% Premium After Successful IPO on NSE and BSE
Frequently Asked Questions
Q1: What is the minimum investment required for Aakaar Medical Technologies IPO?
The minimum investment required for Aakaar Medical Technologies IPO is ₹1,15,200, which corresponds to one lot of 1,600 shares at the upper price band of ₹72 per share. This relatively high minimum investment is typical for SME IPOs and reflects the company’s premium positioning in the aesthetic medical equipment market.
Q2: When will Aakaar Medical Technologies shares be listed and start trading?
Aakaar Medical Technologies shares are scheduled to be listed on the NSE SME platform on June 27, 2025. The IPO timeline includes closure on June 24, 2025, allotment on June 25, 2025, and refund initiation on June 26, 2025, ensuring a quick turnaround from application to listing.
